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Volume 6Available online 23 April 2021Background: Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have
the poorest prognosis. This analysis assessed the efficacy of avelumab plus axitinib versus sunitinib in patients with
treatment-naive advanced sRCC.
Methods: The randomized, open-label, multicenter, phase III JAVELIN Renal 101 trial (NCT02684006) enrolled patients
with treatment-naive advanced RCC. Patients were randomized 1 : 1 to receive either avelumab plus axitinib or sunitinib
following standard doses and schedules. Assessments in this post hoc analysis of patients with sRCC included efficacy
(including progression-free survival) and biomarker analyses.
Results: A total of 108 patients had sarcomatoid histology and were included in this post hoc analysis; 47 patients in the
avelumab plus axitinib arm and 61 in the sunitinib arm. Patients in the avelumab plus axitinib arm had improved
progression-free survival [stratified hazard ratio, 0.57 (95% confidence interval, 0.325-1.003)] and a higher objective
response rate (46.8% versus 21.3%; complete response in 4.3% versus 0%) versus those in the sunitinib arm.
Correlative gene expression analyses of patients with sRCC showed enrichment of gene pathway scores for cancer-
associated fibroblasts and regulatory T cells, CD274 and CD8A expression, and tumors with The Cancer Genome
Atlas m3 classification.
Conclusions: In this subgroup analysis of JAVELIN Renal 101, patients with sRCC in the avelumab plus axitinib arm had
improved efficacy outcomes versus those in the sunitinib arm. Correlative analyses provide insight into this subtype of
RCC and suggest that avelumab plus axitinib may increase the chance of overcoming the aggressive features of sRCC.
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Most patients diagnosed with renal cell carcinoma (RCC)
have clear-cell histology, which is characterized by over-
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- Issue 3 - 2021endothelial growth factor (VEGF).1 Multiple therapies that
target the VEGF/VEGF receptor (VEGFR) pathway have been
approved for the treatment of advanced RCC,2 including the
tyrosine kinase inhibitors (TKIs) sunitinib, cabozantinib,
pazopanib, and axitinib, which are approved for first- and
second-line RCC.2 Although these targeted therapies can be
effective, most patients with advanced RCC ultimately
experience disease progression.3
Among patients with advanced RCC, those with sarco-
matoid differentiation [sarcomatoid RCC (sRCC)] have
the poorest prognosis and experience little benefit withhttps://doi.org/10.1016/j.esmoop.2021.100101 1
ESMO Open T. K. Choueiri et al.single-agent VEGF/VEGFR TKIs.4,5 Sarcomatoid histology is
found in approximately 5% to 8% of all RCCs and can be
associated with all subtypes of RCC.6,7 sRCC has an
aggressive phenotype, with most patients being diagnosed
at an advanced or metastatic stage.5,7 sRCC is also charac-
terized by immunologic infiltration, providing a rationale for
treatment with immune checkpoint inhibitors (ICIs).8 In
addition, compared with tumors without sarcomatoid his-
tology, sRCC tumors exhibit higher expression of the
immune checkpoint proteins programmed death 1 (PD-1)
and programmed death ligand 1 (PD-L1) on tumor-
infiltrating immune cells and tumor cells, respectively.8
ICIs, including the human antiePD-L1 immunoglobulin G1
monoclonal antibody avelumab, have shown manageable
toxicity and durable antitumor activity as first- and second-
line treatments in various tumor types, including advanced
RCC.9-11
In addition to having antiangiogenic effects, VEGFR TKIs
can enhance immune cell tumor infiltration and reduce the
immunosuppressive effects of myeloid-derived suppressor
cells,12,13 suggesting the potential for synergistic antitumor
activity in combination with ICIs. The randomized, phase III
JAVELIN Renal 101 trial (NCT02684006) in previously un-
treated patients with advanced RCC demonstrated signifi-
cantly improved progression-free survival (PFS) with
avelumab plus axitinib versus sunitinib {stratified hazard
ratio (HR), 0.69; [95% confidence interval (CI), 0.56-0.84;
P < 0.001]; median, 13.8 versus 8.4 months} and a higher
objective response rate (ORR; 51.4% versus 25.7%).14 These
results led to the approval of the combination for first-line
treatment of patients with advanced RCC.
A recent retrospective analysis of patients with
sarcomatoid and/or rhabdoid RCC showed better outcomes
in patients receiving ICI-based treatment compared with
patients receiving noneICI-based therapies.15 Furthermore,
the combinations of pembrolizumab (antiePD-1) plus axiti-
nib, nivolumab (antiePD-1) plus ipilimumab (anti-cytotoxic
T-lymphocyte-associated protein 4), and atezolizumab
(antiePD-L1) plus bevacizumab (anti-VEGF) showed
improved efficacy versus sunitinib in patients with sRCC.16-19
Additionally, a recent study evaluating the molecular char-
acterization of rhabdoid and sRCC tumors reported that these
tumors are highly responsive to ICI treatment and have an
immune-inflamed microenvironment, which may help drive
this responsiveness.20 Here, we report results from a post hoc
analysis of patients enrolled in the JAVELIN Renal 101 trial
whose tumors had sarcomatoid features, including correla-
tive gene expression analyses.
METHODS
Patients
The patient eligibility criteria and study design for JAVELIN
Renal 101 have been reported previously.14 Eligible patients
had treatment-naive, histologically or cytologically
confirmed advanced or metastatic RCC with a clear-cell
component. Additional eligibility criteria included age of
18 years (20 years in Japan), Eastern Cooperative
2 https://doi.org/10.1016/j.esmoop.2021.100101Oncology Group performance status (ECOG PS) of 0 or 1,
1 measurable lesion according to RECIST 1.1, a fresh or
archival tumor specimen, and adequate renal, cardiac, bone
marrow, and hepatic function. Patients in all Memorial
Sloan Kettering Cancer Center (MSKCC) and International
Metastatic Renal Cell Carcinoma Database Consortium
(IMDC) prognostic risk groups were eligible.
Trial design, endpoints, and assessments
In this multicenter, randomized, open-label, phase III trial,
patients were randomly assigned (1 : 1) to receive either
avelumab 10 mg/kg intravenously every 2 weeks plus axi-
tinib 5 mg orally twice daily, or sunitinib 50 mg orally once
daily for 4 weeks (6-week cycle). The endpoints and as-
sessments of the overall trial have been reported previ-
ously.14 The primary endpoints were PFS by blinded
independent central review (BICR) according to RECIST 1.1
and overall survival (OS) in patients with PD-L1þ tumors
(1% of immune cells within the tumor area). Secondary
endpoints included efficacy in all treated patients (e.g. PFS,
OS, and objective response). This post hoc analysis included
efficacy assessments in all patients whose pathology report
indicated the presence of any sarcomatoid components
and/or features in the RCC tumor specimen (no central
pathology slide review was carried out) and biomarker an-
alyses that compared pretreatment tumor samples from
patients with and without sarcomatoid histology. The ma-
jority of samples used for the biomarker analysis (w63%)
were derived from tissue collected during nephrectomy,
while the remaining samples were collected from various
metastatic sites.21
Biomarker analyses
PD-L1 expression was assessed by immunohistochemistry in
formalin-fixed, paraffin-embedded (FFPE) tumor samples at a
central laboratory using the Ventana PD-L1 SP263 assay
(Ventana Medical Systems Inc., Tucson, Arizona, USA). A
sample was considered PD-L1þ if the percentage of immune
cells within the tumor area expressing PD-L1 was 1%.
Multiple gene signatures from the Molecular Signatures
Database (MSigDB; including KEGG, Hallmark, Gene
Ontology biological process, and w600 published signa-
tures)22-39 were investigated. Previously published key gene
signatures were defined as follows based on associations
with their respective biology: cancer-associated fibroblast
(CAF) gene signature: COL1A1, COL1A2, COL6A1, COL6A2,
COL6A3, DCN, FAP, and THY122; regulatory T cell (Treg)
cluster: FOXP3 and IL2RA.22 RNA sequencing data from FFPE
tumor samples were summarized into log2 transcripts per
million (TPM) values for individual genes or standardized
gene pathway signature scores [briefly, for each gene, the
mean expression and standard deviation across samples
(collated from both treatment arms) was calculated, then,
for each gene, we subtracted the mean and divided by the
standard deviation to standardize the score to be centered
at zero with units of standard deviation z score]; the
pathway score for each sample was then calculated byVolume 6 - Issue 3 - 2021
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within the pathway. Patients were grouped by the presence
or absence of sarcomatoid features, and their biomarker
data were analyzed using the Data4Cure, Inc. Biomedical
Intelligence Cloud platform (D4C)40 for differences using a
logistic regression model adjusted for age and sex for sar-
comatoid versus nonsarcomatoid samples. Two-sided P
values were calculated using a nonparametric Wilcoxon
rank-sum test.
For RNA sequencing and transcript quantification, whole-
transcriptome profiles were generated for 720 patients (350
in the avelumab plus axitinib arm and 370 in the sunitinib
arm) using RNA-seq [Accuracy and Content Enhanced (ACE)
version 3; Illumina NovaSeq; San Diego, California, USA]
on FFPE tumor tissue, as reported previously.21 Transcript
levels were quantitated by the Personalis ACE Cancer
Transciptome Analysis pipeline using STAR version 2.4.2a-p1
to align reads to the NCBI hs37d5 annotation 105 reference
genome, producing TPM values for each gene. TPM values
were log2 transformed for further analyses. Data were
delivered in eight batches that were inspected by principal
component analysis for potential batch effects. Additionally,
13 of 740 samples with an upper quartile expected count
<700 were excluded. Batch effects were monitored and
mitigated against by the incorporation of controls with
known variants and minor allele frequencies (MAFs) to
ensure that all were detected and that the MAF was what
was expected within a specified window for each run. For
data acceptance, multiple additional sequencing metrics
also had to be met for every run and every specimen within
the run. Finally, before data release, validation data
demonstrating inter-run reproducibility were reviewed and
incorporated into the validation report.
Patient samples were assigned to The Cancer Genome
Atlas (TCGA) m1-m4 subtypes41 using D4C by computing the
Euclidean distance to the nearest subtype centroid. Centroids
were computed using the z score-normalized, top 20% of
variable genes from the TCGA Kidney Renal Clear Cell
Carcinoma gene expression data and the TCGA subtype labels
(ambiguous samples were assigned to the ‘other’ category).
These analyses used log2 normalized RSEM mRNA data from
the TCGA legacy version 20150821 used by D4C. These data
were obtained from Broad GDAC using the firehose_get
utility.42,43 Subtype enrichment was evaluated between the
TCGA subtype distribution of sarcomatoid versus non-
sarcomatoid tumor samples using Pearson’s c2 test.
For the volcano plots, gene signatures [using weighted
gene coexpression network analysis (WGCNA) and Hallmark
gene sets] were compared using a logistic regression model
adjusted for age and sex for sarcomatoid versus non-
sarcomatoid samples. The pathway differences between
sarcomatoid and nonsarcomatoid samples were plotted
based on log10 P value versus logistic regression coeffi-
cient (Wald test). The P values for differences in PFS due to
sarcomatoid status were calculated for continuous pathway
scores and pathway score stratification by median, upper
quartile versus rest, or lower quartile versus rest. The best
P value was used for indicating significant interactions.Volume 6 - Issue 3 - 2021For the elastic net analysis, a multifeature signature was
derived using samples with complete data from the com-
bination arm. For each bootstrap run, we fitted a Cox
proportional hazards model for PFS with regularization by
an elastic net penalty44 and with fivefold cross validation. A
total of 1000 bootstraps were carried out. Features were
ranked by frequency observed in the bootstraps and the
number of top features was selected using a local maximum
concordance index. A composite signature score was
computed by a weighted sum of the top features and each
feature was weighted by its average coefficient across
bootstrap models.Statistical analysis
All results in this manuscript are reported per the data cut-
off for the first interim analysis of this study.14 The pro-
portion of patients with a confirmed objective response was
calculated with corresponding two-sided 95% CIs using the
ClopperePearson method. Time-to-event endpoints were
analyzed using the KaplaneMeier method. Mean duration
of response was calculated per BICR for all patients in this
post hoc analysis using the restricted mean method
described by Huang et al.45,46 In the volcano plot analysis,
the differences in association with prolonged PFS for
the combination arm between sarcomatoid and non-
sarcomatoid samples were analyzed using a logistic
regression model adjusted for age and sex that incorporated
an interaction term for sarcomatoid status.Trial oversight
This trial was conducted in accordance with the ethics
principles of the Declaration of Helsinki and the Interna-
tional Council for Harmonisation Guidelines on Good Clin-
ical Practice. The protocol and amendments were approved
by the institutional review board or independent ethics
committee of each trial center. All patients (or their legal
representatives) provided written informed consent before
enrollment. An independent external data monitoring
committee reviewed efficacy and safety data.
RESULTS
Patients
Of 886 patients with advanced RCC enrolled in JAVELIN
Renal 101 and randomized between 29 March 2016 and 19
December 2017, 108 (12.2%) had sarcomatoid components
and/or features noted in their pathology report (47 patients
in the avelumab plus axitinib arm and 61 in the sunitinib
arm; Supplementary Figure S1, available at https://doi.
org/10.1016/j.esmoop.2021.100101). Baseline characteris-
tics of this subgroup were well balanced and consistent
with those of the overall population (Table 1). Most pa-
tients had an intermediate or poor prognostic risk per
MSKCC and IMDC prognostic factors.
As of 20 June 2018 (data cut-off), the minimum follow-up
from randomization was 6 months. In patients with sRCC,
the median duration of treatment was 6.9 months (range,https://doi.org/10.1016/j.esmoop.2021.100101 3
Table 1. Baseline characteristics of patients with sRCC
Avelumab D
axitinib (N [ 47)
Sunitinib
(N [ 61)
Median age (range), years 60.0 (29.0-73.0) 57.0 (40.0-80.0)
Sex, n (%)
Male 35 (74.5) 52 (85.2)
Female 12 (25.5) 9 (14.8)
Prior nephrectomy, n (%)
Yes 42 (89.4) 55 (90.2)
No 5 (10.6) 6 (9.8)
ECOG PS, n (%)
0 28 (59.6) 33 (54.1)
1 19 (40.4) 27 (44.3)
2 0 1 (1.6)
IMDC prognostic risk group, n (%)
Favorable 6 (12.8) 5 (8.2)
Intermediate 28 (59.6) 39 (63.9)
Poor 13 (27.7) 17 (27.9)
MSKCC prognostic risk group, n (%)
Favorable 6 (12.8) 7 (11.5)
Intermediate 34 (72.3) 44 (72.1)
Poor 7 (14.9) 10 (16.4)
Pooled geographic region, n (%)
North America 20 (42.6) 31 (50.8)
Europe 12 (25.5) 18 (29.5)
Asia 10 (21.3) 6 (9.8)
Rest of the world 5 (10.6) 6 (9.8)
PD-L1 status, n (%)
Positive 34 (72.3) 52 (85.2)
Negative 11 (23.4) 7 (11.5)
Unknown 2 (4.3) 2 (3.3)
ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, Inter-
national Metastatic Renal Cell Carcinoma Database Consortium; MSKCC, Memorial
Sloan Kettering Cancer Center; PD-L1, programmed death ligand 1; sRCC, sarco-
matoid renal cell carcinoma.
ESMO Open T. K. Choueiri et al.0.5-25.3 months) for patients receiving avelumab, 7.2
months (range, 0.07-24.9 months) for patients receiving
axitinib, and 4.2 months (range, 0.4-15.2 months) for pa-
tients receiving sunitinib (Supplementary Table S1, available
at https://doi.org/10.1016/j.esmoop.2021.100101). In this
subgroup, the most common reasons for treatment
discontinuation were progressive disease [avelumab, n¼ 18
(38.3%); axitinib, n ¼ 19 (40.4%); sunitinib, n ¼ 40 (65.6%)]
and adverse event [n ¼ 8 (17.0%), n ¼ 6 (12.8%), n ¼ 3
(4.9%), respectively].
Antitumor activity
Patients with sRCC had improved PFS in the avelumab plus
axitinib arm compared with the sunitinib arm [stratified HR,
0.57 (95% CI, 0.325-1.003); Figure 1A]. Median PFS was 7.0
months (95% CI, 5.3-13.8 months) versus 4.0 months (95%
CI, 2.7-5.7 months), respectively. Within the sarcomatoid
subgroup, deaths from any cause occurred in 11 patients
(23.4%) in the combination arm and 20 (32.8%) in the
sunitinib arm. Although OS data were still immature, the
stratified HR was 0.78 (95% CI, 0.356-1.722). The 12-month
OS rate was 83.0% (95% CI, 67.3% to 91.6%) in the com-
bination arm and 67.0% (95% CI, 51.9% to 78.3%) in the
sunitinib arm.
Of 47 patients in the avelumab plus axitinib arm, 2 (4.3%)
had a confirmed complete response (of whom 1 did not
have measurable disease at baseline) and 20 (42.6%) had a4 https://doi.org/10.1016/j.esmoop.2021.100101partial response. Of 61 patients in the sunitinib arm, 13
(21.3%) had a partial response. The confirmed ORR was
46.8% (95% CI, 32.1% to 61.9%) in the avelumab plus axi-
tinib arm versus 21.3% (95% CI, 11.9% to 33.7%) in the
sunitinib arm (Table 2). Among patients with sRCC who had
a confirmed objective response, the median time to
response was 1.6 months (range, 1.2-9.8 months) in the
combination arm and 3.1 months (range, 1.2-11.1 months)
in the sunitinib arm (Supplementary Figure S2, available at
https://doi.org/10.1016/j.esmoop.2021.100101). Among all
randomized patients with sRCC, patients in the combination
arm had 2.4 months longer mean duration of response
(95% CI, 0.9-3.9 months) than those in the sunitinib arm
(Figure 1B). The best percentage changes from baseline
in the sum of target lesion diameters are shown in
Supplementary Figure S3, available at https://doi.org/10.
1016/j.esmoop.2021.100101.Correlative analyses
Multiple gene signatures from the MSigDB, including
KEGG, Hallmark, Gene Ontology, and w600 published
signatures,22-39 were used to characterize tumor samples
from patients in this post hoc analysis, a number of which
were found to have significantly different expression in pa-
tients with sRCC relative to those with nonsarcomatoid tu-
mors. Of those that were significant, gene signatures
indicative of the presence of CAFs and increased Treg cells
22
were highly significant (Figure 2A) and were notable due to
their relevance to known sRCC biology. These patients also
had reduced expression of key VEGF signaling pathway
molecules (FLT1 and KDR; Figure 2B). In contrast to patients
without sarcomatoid histology, patients with sRCC had
elevated gene expression of CD274 (PD-L1 gene), CD8A,
IFNG, and FOXP3 (Figure 2C). Analyses of differential gene
expression in patients with sRCC compared with those with
nonsarcomatoid tumors, irrespective of treatment arm,
identified key differences between these histologies and
provide additional insight into sRCC biology (Supplementary
Table S2, available at https://doi.org/10.1016/j.esmoop.
2021.100101). Elastic net analysis identified a weighted
gene signature, consisting of PVRL1, SPAG5, SCARNA5,
WASF1, SEC14L4, and GLRX, for which low expression was
associated with a longer PFS for patients with sRCC in the
avelumab plus axitinib arm (Supplementary Figure S4,
available at https://doi.org/10.1016/j.esmoop.2021.100101).
In contrast, expression of this gene signature did not differ-
entiate PFS for patients in the sunitinib arm.
Previous molecular analyses of clear-cell RCC by TCGA
have defined four molecular subtypes based on differen-
tially expressed mRNA signatures (m1-m4). These subtypes
were associated with differential survival, with the m3
subtype being associated with the poorest survival.41 Pa-
tients with sRCC in this analysis had a significantly different
distribution of TCGA subtypes compared with patients with
nonsarcomatoid tumors (P < 0.0001; c2 test) with a marked
enrichment in m3 tumors (54.7% versus 28.1%;
Supplementary Figure S5, available at https://doi.org/10.Volume 6 - Issue 3 - 2021
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Figure 1. Antitumor activity in patients with sRCC. (A) Progression-free survival and (B) mean duration of response based on BICR assessment.
In (B), the difference (avelumab þ axitinib versus sunitinib) in mDR was 2.4 months (95% CI, 0.9-3.9 months), and the truncation time was 12.5 months; duration of
response ¼ PFS time  time to response/PD/death (whichever is earlier).
BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; mDR, mean duration of response; PD, progressive disease; PFS, progression-free
survival; sRCC, sarcomatoid renal cell carcinoma.
a Comparison versus sunitinib.
T. K. Choueiri et al. ESMO Open1016/j.esmoop.2021.100101). Patients with sRCC who had
m3 tumors that also expressed higher levels of CD8A
(n ¼ 36) had longer PFS with avelumab plus axitinib than
with sunitinib (Supplementary Figure S6, available at
https://doi.org/10.1016/j.esmoop.2021.100101). This trend
for improved PFS was not observed in patients whose tu-
mors were characterized as m1 (n ¼ 5), m2 (n ¼ 7), or m4
(n ¼ 5) in the avelumab plus axitinib arm, although patient
numbers were small, or any TCGA subgroup in the sunitinib
arm (Supplementary Table S3, available at https://doi.org/
10.1016/j.esmoop.2021.100101).
By analyzing differences between gene expression and
PFS in patients in the combination arm with and without
sRCC, we identified gene signatures that were associated
with shorter PFS in patients with sRCC compared with those
with nonsarcomatoid tumors (Figure 3). Utilizing WGCNA
gene sets, enrichment of gene pathways including cell cycle
(q value, 2.48E-10), myogenesis (q value, 0.5015), and lipidVolume 6 - Issue 3 - 2021metabolic process (q value, 3.19392E-05) pathways were
associated with shorter PFS in these patients, while cell-to-
cell signaling was associated with prolonged PFS (q value,
5.13011E-06; Figure 3A). Analyses of Hallmark gene sets
also found that cell cycle pathways including G2M check-
point (q value, 4.55E-08), E2F targets (q value, 1.28E-07),
mitotic spindle (q value, 0.0005), and DNA repair (q value,
0.0326), in addition to spermatogenesis (q value, 0.0301),
apical surface (q value, 0.1948), KRAS signaling (q value,
0.6826), estrogen signaling (q value, 0.7041), Notch
signaling (q value, 0.1347), and heme metabolism (q value,
0.0024) were associated with shorter PFS in patients with
sRCC in the combination arm (Figure 3B). Of note, signa-
tures associated with angiogenesis had limited correlation
with prolonged PFS in patients with sRCC in the combina-
tion arm. By analyzing differences in gene expression in
patients in the combination arm using signatures defined by
Chen et al.,47 we found that, compared with samples fromhttps://doi.org/10.1016/j.esmoop.2021.100101 5
Table 2. Antitumor activity among patients with sRCC by BICR
Avelumab D
axitinib (N [ 47)
Sunitinib
(N [ 61)
Confirmed ORR, % (95% CI) 46.8 (32.1-61.9) 21.3 (11.9-33.7)
Odds ratio (95% CI) 3.249 (1.300-8.236) d
Best overall response, n (%)
Complete response 2 (4.3) 0
Partial response 20 (42.6) 13 (21.3)




Progressive disease 7 (14.9) 22 (36.1)
Not evaluable 5 (10.6)a 7 (11.5)b
Median time to response (range),
months
1.6 (1.2-9.8) 3.1 (1.2-11.1)
Difference in mean duration of
response versus sunitinib (95% CI),
months
2.4 (0.9-3.9) d
BICR, blinded independent central review; CI, confidence interval; ORR, objective
response rate; sRCC, sarcomatoid renal cell carcinoma.
a No post-baseline assessments due to early death (n ¼ 1) or other reasons (n ¼ 4).
b No post-baseline assessments due to early death (n ¼ 2), other reasons (n ¼ 1),
patient started new anticancer therapy before first post-baseline assessment (n ¼ 1),
or patient had stable disease <6 weeks after randomization (n ¼ 3).
ESMO Open T. K. Choueiri et al.patients with nonsarcomatoid tumors, sarcomatoid samples
were enriched for an array of cell types, including activated
and resting CD4 memory cells, follicular helper T cells,
CD8þ T cells, activated natural killer cells, M1 and M2
macrophages, gamma delta T cells, Treg cells, and activated
dendritic cells. A gene set for activated CD4þ memory T
cells (q value, 2.18775E-05) was associated with shorter PFS
in patients with sRCC and prolonged PFS in those with
nonsarcomatoid tumors (Figure 3C).
DISCUSSION
In this analysis of the randomized, phase III JAVELIN Renal
101 trial, patients with sarcomatoid components and/or
features in the avelumab plus axitinib arm had improved
efficacy outcomes compared with those in the sunitinib
arm. PFS was prolonged in patients with sRCC in the com-
bination arm versus the sunitinib arm [HR, 0.57 (95% CI,
0.325-1.003)], albeit with a wide 95% CI, which may be due
to the relatively small number of patients included in this
analysis. Time to response was also considerably shorter in
the avelumab plus axitinib versus sunitinib arm (median, 1.6
versus 3.1 months). These results are comparable to those
of additional analyses in patients with sRCC reported for
three other phase III trials investigating first-line ICI-based
combination therapies versus sunitinib for RCC. KEYNOTE-
426, which investigated pembrolizumab plus axitinib in
patients with clear-cell RCC, showed that among 105 pa-
tients with sRCC, those in the combination arm (n ¼ 51)
had improved PFS (HR, 0.54), OS (HR, 0.58), and ORR (58.8%
versus 31.5%) versus those in the sunitinib arm (n ¼ 54).18
CheckMate 214, which investigated nivolumab plus ipili-
mumab in patients with IMDC intermediate/poor-risk clear-
cell RCC, showed that among 139 patients with sRCC, those
in the combination arm (n ¼ 74) had improved PFS (HR,
0.54), OS (HR, 0.45), and ORR (60.8% versus 23.1%) versus
those in the sunitinib arm (n ¼ 65).19 IMmotion151, which
6 https://doi.org/10.1016/j.esmoop.2021.100101investigated atezolizumab plus bevacizumab in patients
with clear-cell RCC and/or sRCC, showed that among 142
patients with sRCC, those in the combination arm (n ¼ 68)
had improved PFS (HR, 0.52), OS (HR, 0.64), and ORR (49%
versus 14%) versus those in the sunitinib arm (n ¼ 74).17
These results, along with findings from a recent meta-
analysis of efficacy in patients with sRCC included in
phase III randomized trials of ICI-based combinations,48
show consistently improved efficacy with ICI-based combi-
nation therapy versus the previous standard of care, suni-
tinib, in patients with sRCC.
The percentage of patients with sRCC in the JAVELIN
Renal 101 trial was higher compared with historical
studies,6,7 but is consistent with the prevalence of sRCC in
recent phase III trials.17-19 This difference in prevalence may
have been due to increased awareness of this variant by
pathologists or the definition for sRCC used in this trial.
Correlative analyses reported here provide insight into
the biology that differentiates the molecular subtypes of
this aggressive form of RCC from nonsarcomatoid disease,
as well as the features of sRCC that are associated with
improved clinical benefit from avelumab plus axitinib
treatment. Most patients with sRCC had m3 tumors, as
defined by the TCGA,41 that are associated with the poorest
survival. Sarcomatoid samples displayed immunosuppres-
sive elements including expression of the CAF and Treg cell
signatures22,23,49 and the PVRL1 gene (also known as nectin-
1 or CD111), which is hypothesized to act in the T-cell
immunoglobulin and ITIM domain (TIGIT) immunomodula-
tory pathway, with overexpression leading to or maintaining
T-cell exhaustion.50 Increased expression of a TIGIT
pathway-associated gene is of particular interest because
blockade of this pathway in combination with PD-1/PD-L1
blockade has shown enhanced antitumor activity in
several preclinical studies.51,52 Additionally, promising clin-
ical activity has been seen in a phase II study investigating
the combination of a PD-L1 inhibitor with an anti-TIGIT
antibody in PD-L1þ NSCLC,53 and multiple other combina-
tion trials are ongoing in various advanced solid tumors.54
Our data support further investigation of this pathway as
a potential therapeutic target for future combination ap-
proaches in patients with sRCC.
In patients who had prolonged PFS with avelumab plus
axitinib treatment, these immunosuppressive characteris-
tics were coupled with features indicative of immune ca-
pacity and activation [e.g. high CD274 (PD-L1 gene), CD8A,
and IFNG expression], which may contribute to both the
poorer prognosis for patients with sRCC treated with single-
agent VEGF/VEGFR inhibitors4,5 and their improved
response to treatment with avelumab plus axitinib. Addi-
tionally, this observation is consistent with findings from a
recent molecular characterization study of rhabdoid and
sRCC tumors from both clinical trials and real-world cohorts,
which reported that these tumors have an immune-
inflamed phenotype with increased immune activation,
CD8þ T-cell infiltration, and PD-L1 expression.20 Another
notable finding in our study was that angiogenesis-related
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Figure 2. An overview of the biomarker profile of patients with sRCC showing (A) presence of CAFs and Treg cells, (B) lower expression of key VEGF signaling
molecules, and (C) elevated CD274, CD8A, IFNG, and FOXP3 gene expression.
Triangle symbol in the boxes represents the mean and the horizontal line represents the median; upper and lower box lines represent the 3rd and 1st quartile,
respectively. Sample numbers per group are given above each plot. Two-sided P values calculated using a nonparametric Wilcoxon rank-sum test.
CAF, cancer-associated fibroblasts; TPM, transcripts per million; Treg, regulatory T cell; sRCC, sarcomatoid renal cell carcinoma; VEGF, vascular endothelial growth factor.
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Figure 3. Differences in expression and progression-free survival in the combination arm between sarcomatoid and nonsarcomatoid samples according to
(A) WGCNA clusters, (B) Hallmark pathways, and (C) cell type-specific signatures.
For the expression analysis, there were 97 sarcomatoid samples and 618 nonsarcomatoid samples; for the progression-free survival analysis, there were 39 sarcomatoid
samples and 310 nonsarcomatoid samples. A positive coefficient indicates that the signature/pathway is expressed at higher levels in sarcomatoid versus non-
sarcomatoid samples, and a negative coefficient indicates that a signature/pathway is expressed at higher levels in nonsarcomatoid versus sarcomatoid samples. Dots
above the dashed line denote gene expression pathways or signatures that were statistically different (P  0.05) in expression between sarcomatoid and non-
sarcomatoid samples. Blue dots indicate a significantly shorter progression-free survival in sarcomatoid samples with higher pathway score (P  0.05), whereas purple
dots indicate a significantly shorter progression-free survival in nonsarcomatoid samples with higher pathway score (P  0.05). For (C), only positive coefficients
(signatures/pathways that are expressed at higher levels in sarcomatoid versus nonsarcomatoid samples) are shown.
EMT, epithelialemesenchymal transition; IL-6, interleukin-6; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; NF-kB,
nuclear factor kappa B; NK, natural killer; PI3K, phosphoinositide 3-kinases; STAT, signal transducer and activator of transcription; TGF, transforming growth factor; TNF,
tumor necrosis factor; WGCNA, weighted gene coexpression network analysis.
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Figure 3. (Continued)
T. K. Choueiri et al. ESMO Openprolonged PFS in the combination arm, and the expression
of genes associated with hypoxia and glycolytic pathway
activation were not associated with prolonged PFS. Further
studies are needed to determine whether ICI monotherapy
would provide similar benefits to combination ICI and TKI
therapy in this population.
Based on the correlative analyses reported here, ele-
ments of both the adaptive and innate immune systems are
likely contributing to the potential for an improved clinical
benefit in patients with sRCC who receive the immunosti-
mulatory combination of avelumab plus axitinib and other
ICI-based combinations.
This study had limitations. Firstly, the trials’ eligibility
criteria included an ECOG PS of 0-1; therefore, a proportionVolume 6 - Issue 3 - 2021of patients with poorer prognosis will have been excluded,
which may hinder interpretation of the results versus real-
world practice. Secondly, no central pathology slide re-
view was carried out, which may have led to alternative
classifications. Additionally, although w63% of tissues
analyzed in the biomarker analyses were collected from
nephrectomy specimens, the remaining tissues were taken
from various metastatic sites, which may exhibit tumor
heterogeneity.Conclusions
The findings from this subgroup analysis of the JAVELIN Renal
101 trial suggest that the combination of avelumab andhttps://doi.org/10.1016/j.esmoop.2021.100101 9
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ESMO Open T. K. Choueiri et al.axitinib had clinical benefit versus sunitinib in patients with
sRCC andmay counteract the aggressive features of sRCC that
hinder efficacy of single-agent VEGFR pathway inhibitors.ACKNOWLEDGEMENTS
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